Nimenrix

Meningococcal polysaccharide serogroups A, C, W-135 & Y conjugate vaccine

Active immunization of individuals from 6 wk against invasive meningococcal diseases caused by Neisseria meningitidis groups A, C, W-135 & Y.

IM Adult, adolescent & childn ≥12 mth Administer 0.5 mL single dose. Unvaccinated infant from 6 mth to <12 mth Primary immunization: Administer 0.5 mL single dose. Booster: At 12 mth, administer w/ a min interval of at least 2 mth after primary dose. Infant from 6 wk to <6 mth Primary immunization: Administer 2 doses (0.5 mL/dose) w/ the 1st dose given from 6 wk w/ a 2-mth dose interval. Booster: Administer at 12 mth. Previously vaccinated adult, adolescent & childn ≥12 mth May be given as a booster dose to individuals who have previously received primary vaccination w/ conjugated or plain polysaccharide meningococcal vaccine. Individual w/ underlying predisposing conditions to meningococcal infection due to anatomic/functional asplenia (eg, sickle cell disease) At least 1 dose may be given.

Hypersensitivity.

Do not administer intravascularly, intradermally or SC. Review patient's medical history (especially previous vaccination) & clinical examination. Postpone in patients w/ acute severe febrile illness. Syncope can occur following or before any vaccination. Individuals w/ thrombocytopenia or any coagulation disorder. Increased risk for invasive disease caused by Neisseria meningitidis groups A, C, W-135 & Y in patients w/ certain complement deficiencies & those receiving treatment that inhibits terminal complement activation (eg, eculizumab) even if they develop Ab following vaccination w/ Nimenrix. Patients receiving immunosuppressive treatment or those w/ immunodeficiency may not elicit an adequate immune response. Individuals w/ increased susceptibility to meningococcal infection due to anatomic/functional asplenia (eg, sickle cell disease). Not a protection against other Neisseria meningitidis groups. Consider 2nd primary dose after a 2-mth interval if infant (6 to <12 mth) or toddler is expected to be at immediate risk of invasive meningococcal disease due to the exposure to groups W-135 &/or Y. Consider booster dose if an individual is expected to be at particular risk of exposure to group A & has previously received a dose approx >1 yr; in individuals remaining at high risk of exposure to meningococcal disease caused by groups A, C, W-135 & Y. Not a substitute for tetanus immunization. Pregnancy & lactation.

Appetite loss; irritability; drowsiness, headache; fever, inj site swelling, pain & redness, fatigue. GI symptoms (including diarrhoea, vomiting & nausea); inj site haematoma.

Co-administer w/ tetanus toxoid (TT) containing vaccine (eg, DTaP/IPV/Hib/HepB vaccine) or administer Nimenrix at least 1 mth before the TT-containing vaccine. If to be given at the same time as another inj vaccines, the vaccines should always be administered at different inj sites. Patients receiving immunosuppressive treatment may not elicit adequate response.

Vaccines, Antisera & Immunologicals

J07AH08 - meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated ; Belongs to the class of meningococcal bacterial vaccines.

POM